Skip to content

Affinity: Hospital Trial

Affinity: Hospital Trial. Early Prototype Testing for a Home Oncology Monitoring System

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04211727
Enrollment
247
Registered
2019-12-26
Start date
2020-10-26
Completion date
2022-01-17
Last updated
2022-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Oncology, Cancer

Brief summary

Method comparison study to compare the Affinity prototype device using a capillary blood sample against routine venous laboratory results, in patients undergoing systemic anti-cancer therapy (SACT). Tests will be performed by healthcare professionals (Cohort 1) and participants self-testing (Cohort 2)

Detailed description

In this study the Investigators wish to compare 200 finger prick sample (capillary) blood results taken and analysed using the Affinity prototype device to standard of care venous blood samples, taken from the participant on the same day. The blood tests will analyse Full Blood Count (FBC) 200 patients will be recruited in total. 100 will take part in Cohort 1, where a member of the clinical research team will take their blood sample using the Affinity prototype device. The other 100 will take part in Cohort 2, where the participant will self test and take the blood sample themselves. Participants will be asked to complete a short questionnaire after using the device to provide any feedback on its design and use.

Interventions

DIAGNOSTIC_TESTCapillary finger prick blood sample

Patients will have a blood finger prick sample

Sponsors

The Christie NHS Foundation Trust
CollaboratorOTHER
Entia Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years old at the time of study entry Currently receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle * Scheduled to be undergoing routine venous laboratory blood tests as part of standard of care * Can provide written informed consent * Cohort 2 only- Able to independently complete participant questionnaires

Exclusion criteria

* Receiving systemic anti-cancer therapy for a haematological malignancy * Known parasitic infection * Known inherited or acquired bleeding disorder * History of haematological malignancy * Known poorly controlled anti-coagulation * Cohort 2 only- Participant or carer unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result

Design outcomes

Primary

MeasureTime frameDescription
To assess the accuracy (bias) of the Affinity prototype device against laboratory testing (capillary vs. venous sample)1 yearMeasuring Full Blood Count (FBC)

Secondary

MeasureTime frameDescription
Assessment and feedback1 yearTo measure the number of issues when the prototype device is used by healthcare professionals (Cohort 1) and participants (Cohort 2).

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026